Qianwei Liu, MD, PhD; Fen Yang, MD, PhD; Krisztina D. László, PhD; et al.
JAMA Oncol. 2024;10(10):1323-1330. doi:10.1001/jamaoncol.2024.3036
This cohort study evaluates the risk of suicide attempt and suicide death among spouses of patients with a cancer diagnosis in Denmark.
-
Editorial
Hidden Morbidity in Cancer Care—Mental Health in Spouses
Casey Crump, MD, PhD; Weiva Sieh, MD, PhD
JAMA Oncol
Guillermo Villacampa, MSc; Victor Navarro, MSc; Alexios Matikas, MD, PhD; et al.
JAMA Oncol. 2024;10(10):1331-1341. doi:10.1001/jamaoncol.2024.3456
This meta-analysis examines the efficacy outcomes and safety profile of immune checkpoint inhibitors in combination with adjuvant chemotherapy in patients with early breast cancer across molecular phenotypes.
-
Editorial
Neoadjuvant Immunotherapy—From Trials to Practice
Elizabeth A. Mittendorf, MD, PhD, MHCM; Sara M. Tolaney, MD, MPH
JAMA Oncol
Min Hee Hong, MD; Yoon Ji Choi, MD, PhD; Hee Kyung Ahn, MD, PhD; et al.
open access
JAMA Oncol. 2024;10(10):1342-1351. doi:10.1001/jamaoncol.2024.2640
This nonrandomized controlled trial investigates central nervous system (CNS) activity with lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Daniel R. Sikavi, MD; Kai Wang, PhD; Wenjie Ma, ScD; et al.
JAMA Oncol. 2024;10(10):1354-1361. doi:10.1001/jamaoncol.2024.2503
This cohort study examines the use of regular aspirin use as a preventive intervention in individuals with varying risk factors for colorectal cancer.
Eli Muchtar, MD; Brendan Wisniowski, MBBS; Susan Geyer, PhD; et al.
JAMA Oncol. 2024;10(10):1362-1369. doi:10.1001/jamaoncol.2024.2629
This cohort study examines graded kidney response criteria and their association with kidney and overall survival for patients with kidney light chain amyloidosis.
Julia S. Wong, MD; Hajime Uno, PhD; Angela C. Tramontano, MPH; et al.
JAMA Oncol. 2024;10(10):1370-1378. doi:10.1001/jamaoncol.2024.2652
This randomized clinical trial compares the outcomes of hypofractionation vs conventional fractionation postmastectomy radiation therapy regimens in patients undergoing implant-based breast reconstruction.
Ruth M. O’Regan, MD; Yi Zhang, PhD; Gini F. Fleming, MD; et al.
JAMA Oncol. 2024;10(10):1379-1389. doi:10.1001/jamaoncol.2024.3044
This prospective-retrospective translational study of patients enrolled in SOFT assesses the predictive and prognostic performance of the Breast Cancer Index for ovarian function suppression benefit in premenopausal women with hormone receptor–positive breast cancer.
Dorte Lisbet Nielsen, MD, DMSc; Carsten Bogh Juhl, MPH, PhD; Ole Haagen Nielsen, MD, DMSc; et al.
JAMA Oncol. 2024;10(10):1390-1399. doi:10.1001/jamaoncol.2024.3065
This systematic review and meta-analysis updates data on the incidence of cardiovascular adverse events in clinical trials of immune checkpoint inhibitors alone and in combination therapies and provides recommendations for management among patients treated for cancer.
Catherine H. Marshall, MD; Benjamin A. Teply, MD; Jiayun Lu, PhD; et al.
JAMA Oncol. 2024;10(10):1400-1408. doi:10.1001/jamaoncol.2024.3074
This nonrandomized controlled trial aims to determine the activity of olaparib monotherapy among patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy.
Karina N. Ruiz-Esteves, MD; Kaitlyn R. Shank, MD; Aaron J. Deutsch, MD; et al.
has audio
JAMA Oncol. 2024;10(10):1409-1416. doi:10.1001/jamaoncol.2024.3104
This cohort study examines the incidence, risk factors, and clinical spectrum of immune checkpoint inhibitor–induced diabetes.
-
Audio:
Identification of Immune Checkpoint Inhibitor–Induced Diabetes